{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 28,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/22",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.21,
        "x": 0.07,
        "y": 0.308
      },
      "kind": "image",
      "text": "Pfizer logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce1b3b5a-afd2-4e3a-9bde-095fdf5490e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.21,
        "x": 0.07,
        "y": 0.64
      },
      "kind": "image",
      "text": "Fosun Pharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db9b8cba-b840-48cf-a908-9752dfa1def8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.23,
        "y": 0.56
      },
      "kind": "list",
      "text": "Co-development with Fosun Pharma to hold exclusive marketing rights in China if approved; Combined upfront payment and equity investment of $51 million to BioNTech received in April; Fosun Pharma to fund development expenses in China; BioNTech and Fosun to share gross profits on the sale of the vaccine in China; BioNTech eligible to receive further China development & sales milestones up to $84 million",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e295b4a-0042-49c9-8689-dd319691cddc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.23,
        "y": 0.24
      },
      "kind": "list",
      "text": "Co-development and Co-commercialization worldwide (ex China) if approved; Combined upfront payment and equity investment of $185 million to BioNTech received in April; Capital expenditures to be funded by each party independently; Companies to share development expenses and gross profits on a 50:50 basis; BioNTech eligible to receive further development & sales milestones up to $563 million",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faab6463-47b5-4d61-9d3f-f8ca50ffaae9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT162 Commercial update",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05e6e746-9895-4aaf-bb0e-40caa595527a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2d63a4bb-eac5-4ad4-af8a-239c6423af72",
      "evidence": "The slide appears to be directed towards investors or stakeholders, indicating a specific audience definition.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 21,
      "beatId": "e917a87d-2b75-411a-b926-1b30683902ca",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with an outlook for 2H 2020 and a Q&A session",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}